Volume 5.11 | Mar 25

Hematopoiesis News 5.11 March 25, 2014
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
 
TOP STORY
Ionizing Irradiation Induces Acute Hematopoietic Syndrome and Gastrointestinal Syndrome Independently in Mice
Researchers used bone marrow (BM) transplantation, total body irradiation and abdominal irradiation models to demonstrate a very limited, if any, role of BM-derived cells in acute gastrointestinal injury and recovery. [Nat Commun] Abstract
Enter to Win a Travel Award to ISSCR 2014
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Image-Guided Intrathymic Injection of Multipotent Stem Cells Supports Life-Long T Cell Immunity and Facilitates Targeted Immunotherapy
Scientists showed that intrathymic injection of multipotent hematopoietic stem/progenitor cells into irradiated syngeneic or allogeneic young or aged recipients resulted in efficient and long-lasting generation of functional donor T cells. [Blood] Abstract

The Co-Repressor Rcor1 Is Essential for Murine Erythropoiesis
Researchers showed that mice deleted for Rcor1 are profoundly anemic and die in late gestation. Definitive erythroid cells from mutant mice arrest at the transition from proerythroblast to basophilic erythroblast. [Blood] Abstract

Parathyroid Hormone Enhances Hematopoietic Expansion via Upregulation of Cadherin-11 in Bone Marrow Mesenchymal Stromal Cells
When parathyroid hormone-treated bone marrow mesenchymal stromal cells were subcutaneously implanted into NOD/SCID mice, the induction of hematopoietic cells was enhanced. [Stem Cells] Abstract

Effects of THAP11 on Erythroid Differentiation and Megakaryocytic Differentiation of K562 Cells
Scientists showed that THAP11 was down-regulated during erythroid differentiation but up-regulated during megakaryocytic differentiation of cord blood CD34+ cells. Overexpression of THAP11 in K562 cells inhibited the erythroid differentiation induced by hemin with decreased numbers of benzidine-positive cells and decreased mRNA levels of α-globin and glycophorin A, and knockdown of THAP11 enhanced the erythroid differentiation. [PLoS One] Full Article

The Bone Marrow Hematopoietic Microenvironment Is Impaired in Iron-Overloaded Mice
Increasing numbers of reports have described hematopoietic improvement after iron chelation therapy in iron-overloaded patients. These observations indicate that excess iron could affect hematopoiesis unfavorably. To investigate how excess iron affects hematopoiesis in vivo, investigators generated iron-overloaded mice and examined hematopoietic parameters in these mice. [Eur J Haematol] Abstract

Identification of Multipotent Progenitors that Emerge Prior to Hematopoietic Stem Cells in Embryonic Development
Researchers found that, during the initiation of definitive hematopoiesis in the embryo, a defined population of multipotent, engraftable progenitors emerges that is much more abundant within the yolk sac than the aorta-gonad-mesonephros or fetal liver. [Stem Cell Rep] Full Article | Press Release

Divisional History and Hematopoietic Stem Cell Function during Homeostasis
The authors investigated the homeostatic behavior of hematopoietic stem and progenitor cells (HSPCs) temporally defined according to their divisional histories using an HSPC-specific GFP label-retaining system. They showed that homeostatic hematopoietic stem cells lose repopulating potential after limited cell divisions. [Stem Cell Rep] Full Article

CLINICAL RESEARCH

Outcome of Patients with abnl(17p) Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
In order to accurately define the outcome after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with abnormalities of chromosome 17p (abnl(17p)) acute myeloid leukemia (AML), researchers analyzed the results of patients with this abnormality who received an allogeneic HSCT in one of four well defined cohorts (FHCRC, HOVON, SAL, GCTSG). [Blood] Abstract

Allotransplantation for Patients Age 40 Years and Greater with Non-Hodgkin Lymphoma (NHL): Encouraging Progression-Free Survival
Investigators analyzed CIBMTR data on 1248 patients ≥40 years receiving reduced-intensity conditioning or non-myeloablative allogeneic hematopoietic cell transplantation for aggressive and indolent NHL. [Biol Blood Marrow Transplant] Abstract

Learn more about the new smartphone app for human blood cell frequencies
 
REVIEWS
Co-Operating STAT5 and AKT Signaling Pathways in Chronic Myeloid Leukemia and Mastocytosis: Possible New Targets of Therapy
This review provides an overview of the current knowledge about the critical role of AKT and STAT5 in the pathophysiology of chronic myeloid leukemia and systemic mastocytosis and on their potential value as therapeutic targets in these neoplasms. [Haematologica] Full Article

Cholesterol and Hematopoietic Stem Cells: Inflammatory Mediators of Atherosclerosis
Recent findings have provided new insight into the interaction among hematopoietic stem cells, cholesterol, and atherosclerosis. In mice, high cholesterol levels or inactivation of cholesterol efflux transporters have multiple effects on hematopoietic stem cells (HSPCs), including promoting their mobilization into the bloodstream, increasing proliferation, and differentiating HSPCs to the inflammatory monocytes and neutrophils that participate in atherosclerosis. [Stem Cells Transl Med] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
 
INDUSTRY NEWS
Cerebral Palsy and the Potential of Cord Blood Stem Cells
Cord Blood Registry® is partnering with two preeminent institutions, the University of Texas Health Science Center at Houston and Georgia Regents University, to establish FDA-regulated clinical trials investigating whether an intravenous infusion of a child’s own cord blood cells, banked at the time of their birth, will lessen the symptoms of cerebral palsy. [PR Newswire Association LLC] Press Release

Igenica Enrolls First Patient in Phase I Trial of IGN523 to Treat Acute Myeloid Leukemia
Igenica Biotherapeutics announced that the first patient has been dosed in a Phase I clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML). The trial is designed to assess the safety, pharmacokinetics and clinical activity of IGN523, an antibody targeting CD98, a cell surface protein frequently overexpressed on AML cells. [Igenica, Inc.] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 2014 Highlights of American Society of Hematology (ASH) in Latin America
April 25-26, 2014
Florianópolis, Brazil

NEW Society for Developmental Biology 73rd Annual Meeting
July 17-21, 2014
Seattle, United States

Visit our events page to see a complete list of events in the hematopoiesis research community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellow – Hematopoietic Stem Cell and Leukemia Research (City of Hope)

Postdoctoral Position – Immunotherapies for Cancer Based on Genetic Engineered T Lymphocytes and/or Hematopoietic Stem Cells (Roswell Park Cancer Institute)

Postdoctoral Fellow – Mammalian Hematopoietic and Erythroid Development (The Icahn School of Medicine at Mount Sinai)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Postdoctoral Position – Human Stem Cell Biology and Hematopoiesis (Johns Hopkins University School of Medicine)

Postdoctoral Position – Stem Cell Biology (St. Jude Children’s Research Hospital)

Postdoctoral Position – Genes that Regulate Hematopoietic Stem Cells (University of Chicago)

Postdoctoral Position – Hematopoietic Stem Cell Biology (St. Jude Children’s Research Hospital)

Postdoctoral Position – Hematopoietic Stem Cell Physiology and Bone Marrow Failure (University of Michigan)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us